{
  "source": "PA-Med-Nec-Xifaxan.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2030-15\nProgram Prior Authorization/Medical Necessity\nMedication Xifaxan® (rifaximin)\nP&T Approval Date 8/2014, 7/2015, 10/2015, 10/2016, 10/2017, 4/2018, 4/2019, 4/2020,\n4/2021, 04/2022, 7/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nXifaxan is an antibacterial agent indicated for the treatment of travelers’ diarrhea caused by\nnoninvasive strains of Escherichia coli in patients 12 years of age and older, for the risk\nreduction of hepatic encephalopathy recurrence in adults and for the treatment of irritable\nbowel syndrome with diarrhea (IBS-D). There is limited data to support the off label use of\nXifaxan for the treatment of inflammatory bowel disease.\nThis program requires a member to try a lower cost alternative before providing coverage for\nXifaxan. Members utilizing Xifaxan 200 mg for Travelers’ Diarrhea will automatically be\napproved if prescribed for a one-time dose of 9 tablets.\n2. Coverage Criteriaa:\nA. Travelers’ Diarrhea\n1. Authorization\na. Xifaxan will be approved based on both of the following criteria:\n(1) Travelers’ diarrhea\n-AND-\n(2) History of failure, contraindication or intolerance to one of the following:\n(a) Azithromycin (generic Zithromax)\n(b) Ciprofloxacin (generic Cipro)\n(c) Levofloxacin (generic Levaquin)\n(d) Ofloxacin (generic Floxin)\nAuthorization will be issued for one month\nB. Hepatic Encephalopathy\n1. Initial Authorization\na. Xifaxan will be approved based on both of the following criteria:\n(1) Hepatic Encephalopathy\n© 2024 UnitedHealthcare Services Inc.\n1\n-AND-\n(2) One of the following\n(a) Both of the following:\ni. Used as add-on therapy to lactulose\n-AND-\nii Patient is unable to achieve an optimal clinical response with lactulose\nmonotherapy\n-OR-\n(b) History of contraindication or intolerance to lactulose\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Xifaxan will be approved based on the following criterion:\n(1) Documentation",
    "b) History of contraindication or intolerance to lactulose\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Xifaxan will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Xifaxan therapy\nAuthorization will be issued for 12 months\nC. Irritable Bowel Syndrome with diarrhea (IBS-D)\n1. Initial Authorization\na. Xifaxan will be approved based on all of the following criteria:\n(1) Diagnosis of IBS-D\n-AND-\n(2) History of failure, contraindication or intolerance to a tricyclic antidepressant\n(e.g. amitriptyline)\n-AND-\n(3) One of the following:\na) History of failure, contraindication or intolerance to Viberzi\n-OR-\nb) History of or potential for a substance abuse disorder\n© 2024 UnitedHealthcare Services Inc.\n2\nAuthorization will be issued for 14 days\n2. Reauthorization\na. Xifaxan will be approved based on all of the following criteria:\n(1) Patient has experienced a recurrence of IBS-D after a prior 14 day course of\ntherapy with Xifaxan\n(2) Patient has had a treatment-free period between courses of therapy\n(3) Patient has not already received 3 treatment courses of Xifaxan for IBS-D in the\nprevious 6 months\nAuthorization will be issued for 14 days\nD. Inflammatory Bowel Disease (e.g. Crohn’s Disease, Ulcerative Colitis, Diverticulitis)\n(Off Label)\n1. Initial Authorization\na. Xifaxan will be approved based on both of the following criteria:\n(1) Diagnosis of Inflammatory Bowel Disease\n-AND-\n(2) History of failure, contraindication or intolerance to both of the following:\n(a) Ciprofloxacin (generic Cipro)\n(b) Metronidazole (generic Flagyl)\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Xifaxan will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Xifaxan therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other p",
    "rapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services Inc.\n3\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may apply\n4. References:\n1. Xifaxan [package insert]. Bridgewater, NJ: Bausch Health US, LLC; October 2023.\n2. Prantera C , Lochs H , Grimaldi M et al. Rifaximin-extended intestinal release induces\nremission in patients with moderately active Crohn's disease . Gastroenterology 2012 ;\n142 : 473 – 81 . e4\n3. LaRocque, R. Travelers’s diarrhea: Treatment and prevention. In:UpToDate, Calderwood, SB\n(Ed), UpToDate. Waltham, MA. (Accessed on May 2023).\n4. Pimentel H, Lembo A, Chey W, et al: Rifaximin therapy for patients with Irritable Bowel\nSyndrome without constipation. N Engl J Med 2011; 364(1):22-32\n5. Lacey, BE, Pimentel, M, Brenner, DM, et. al. ACG Clinical Guideline: Management of Irritable\nBowel Syndrome. Am J Gastroenterol. 2021; 116 (1): 17-44.\n6. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel\nSyndrome With Diarrhea. Gastroenterology. 2022.\n7. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014\nPractice Guideline by the American Association for the Study of Liver Diseases and the European\nAssociation for the Study of the Liver. Hepatology. 2014;60:715-735.\n8. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020; 115:\n165-78.\nProgram Prior Authorization/Medical Necessity – Xifaxin\nChange Control\nDate Change\n8/2014 New program.\n9/2014 Adm",
    "ideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020; 115:\n165-78.\nProgram Prior Authorization/Medical Necessity – Xifaxin\nChange Control\nDate Change\n8/2014 New program.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n7/2015 Annual Review. Added irritable bowel syndrome with diarrhea (IBS-\nD)\n10/2015 Updated Step 1 agents for IBS-D. Updated references.\n7/2016 Added Indiana and West Virginia coverage information.\n10/2016 Updated Step 1 agents for IBS-D. Updated references.\n11/2016 Added California coverage information.\n10/2017 Annual review. Updated background and state mandate information.\nReferences updated.\n4/2018 Updated criteria for hepatic encephalopathy. Updated references.\n8/2018 Administrative update due to correct typo.\n4/2019 Annual review. Added statement regarding use of automated processes\nand updated references.\n4/2020 Annual review. Updated references.\n4/2021 Annual review. Removed antispasmodic and antidiarrheal agent as a\nstep 1 option for IBS-D based on updated ACG guidelines. Added\nreauthorization for hepatic encephalopathy. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n4\n4/2022 Annual review. No changes.\n7/2022 Added step requirement of Viberzi for IBS-D.\n7/2023 Annual review. Updated references.\n7/2024 Annual review. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n5"
  ]
}